home       
   
 
 
 
Biotecnol is a biopharmaceutical company focusing on the discovery, engineering and development of novel multifunctional antibody molecules, directed to key therapeutic targets. Using its Tribody™ technology, Biotecnol is developing a pipeline of products for applications in major disease areas such as oncology.
 
Biotecnol applies its antibody technologies, product development and manufacturing experience to generate, support and out-license human antibody products. Biotecnol SA carries its product development activities via its fully owned subsidiary Biotecnol Pharma, Inc., based in Durham, NC, USA.
Through its headquarters in Portugal, Biotecnol leverages its business income by establishing in-house partner-led or collaborative programmes, which provide Biotecnol a strong client-based activity and an established track record. Biotecnol uses its proprietary expression technology, cell line development capabilities, upstream and downstream processing, analytics and QC experience for delivering GMP/GLP compliant processes for biomanufacturing.

 
 
Biotecnol has various types of proprietary antibody products in various stages of development against a number of cancer targets. Biotecnol is committed in building value by developing a diverse pipeline of antibody products to address unmet healthcare needs.